Related Experiment Video
Updated: May 15, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Oral propranolol for treatment of pediatric capillary hemangiomas
Maryam Aletaha1, Hossein Salour, Abbas Bagheri
1Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Insights
Oral propranolol effectively treats pediatric capillary hemangiomas, showing significant improvement within two months. This study indicates propranolol is a safe and effective first-line treatment for these common childhood vascular lesions.
Area of Science:
- Pediatric Dermatology
- Ophthalmology
- Pharmacology
Background:
- Capillary hemangiomas are common benign vascular tumors in infants.
- Periocular hemangiomas can cause significant visual impairment and cosmetic concerns.
- Limited effective and safe treatment options have historically been available.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of oral propranolol for treating pediatric periocular capillary hemangiomas.
- To assess the treatment response and potential complications associated with propranolol therapy.
Main Methods:
- Three infants with periocular capillary hemangiomas were treated with oral propranolol (2-3 mg/kg/day).
- Treatment was administered for up to one year of age, followed by a gradual taper.
- Infants were monitored for 20 months to assess lesion evolution and treatment outcomes.
Main Results:
- All patients demonstrated significant improvement within the first two months of therapy.
- A continuous and slow positive effect was observed throughout the 20-month follow-up period.
- No serious adverse complications were reported during the treatment course.
Conclusions:
- Oral propranolol is a safe and effective first-line treatment for pediatric capillary hemangiomas.
- The drug facilitates rapid and sustained regression of these vascular lesions.
- Propranolol offers a promising therapeutic option for improving outcomes in affected children.
Purpose:
To report the long-term results of treatment of pediatric capillary hemangiomas with oral propranolol.
Methods:
Three infants, 3 to 4 months of age, with periocular capillary hemangiomas were treated with oral propranolol solution (Inderal, 20mg/5ml) 2-3 mg/kg per day divided in 2 doses. Propranolol was continued up to the end of the first year of life and tapered over 2-3 weeks. All infants were followed for 20 months. Lesion size and evolution were assessed during the follow-up period.
Results:
Significant improvement was noted in all patients in the first 2 months of therapy with slow and continuous effect throughout the follow-up period. No serious complications were observed.
Conclusion:
Oral propranolol can be used as a first line agent in children with capillary hemangiomas.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Types of β-Blockers